Tumour–Stroma Ratio as a Predictive Biomarker for Neoadjuvant Therapy Efficacy in Rectal Cancer
Cancers · 27.06.2026 · 18 (13) · 2089
DOI: 10.3390/cancers18132089 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.06.2026. Verfasst von Jonathan P Callaghan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, Leeds LS9 7TF, UK. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK Leeds Radiotherapy Research Centre of Excellence, Yorkshire Cancer Research programme grant, National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre.
Abstract (Originalsprache)
Background
The treatment of rectal cancer frequently involves a multimodal approach, including neoadjuvant therapy prior to surgery in patients with locally advanced disease. However, the response to such treatment is variable. Robust biomarkers to predict neoadjuvant therapy response represent an unmet clinical need; they could help to stratify patients for organ preservation strategies or treatment intensification. The tumour–stroma ratio (TSR) is an established prognostic marker that has recently gained attention for its potential predictive value when assessed in pre-treatment biopsies.
Objective
This narrative review critically evaluates the existing evidence regarding TSR as a predictive biomarker for neoadjuvant therapy response in rectal cancer.
Results
Emerging evidence from retrospective studies of large cohorts suggests that stroma-high tumours often demonstrate resistance to standard neoadjuvant chemoradiotherapy, resulting in lower major pathological response rates. Conversely, some smaller studies report no significant association between biopsy TSR and treatment efficacy. This conflicting evidence could be attributable to methodological heterogeneity, including inconsistent definitions, varying measurement techniques (manual versus automated), and mixed patient cohorts. The predictive value of TSR appears to be neoadjuvant regimen-specific, with stroma-high phenotypes interacting differently with treatments like short-course radiotherapy or intensified chemotherapy.
Conclusions
TSR is a simple, biologically plausible, and readily assessable promising biomarker with apparently predictive as well as prognostic potential. It is likely to represent a regimen-specific predictor rather than a universal marker of resistance to neoadjuvant therapy in rectal cancer. Future clinical translation will require standardised, AI-driven quantification and robust prospective clinical validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, Leeds LS9 7TF, UK.
ORCID-Profile: Jonathan P Callaghan, Nicholas P West
Förderung
- Cancer Research UK Leeds Radiotherapy Research Centre of Excellence
- Yorkshire Cancer Research programme grant
- National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre
Zitieren
APA
Callaghan, J. P., Cartlidge, C. R., Patel, K., & West, N. P. (2026). Tumour–Stroma Ratio as a Predictive Biomarker for Neoadjuvant Therapy Efficacy in Rectal Cancer. Cancers, 18(13), 2089. https://doi.org/10.3390/cancers18132089
Vancouver
Callaghan JP, Cartlidge CR, Patel K, West NP. Tumour–Stroma Ratio as a Predictive Biomarker for Neoadjuvant Therapy Efficacy in Rectal Cancer. Cancers. 2026;18(13):2089. doi:10.3390/cancers18132089
BibTeX
@article{Callaghan2026,
author = {Callaghan, Jonathan P and Cartlidge, Caroline R and Patel, Kenal and West, Nicholas P},
title = {Tumour–Stroma Ratio as a Predictive Biomarker for Neoadjuvant Therapy Efficacy in Rectal Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2089},
doi = {10.3390/cancers18132089}
}
EUVIMED